Multiple Sclerosis Following SARS-CoV-2 Infection

Overview

Journal Mult Scler Relat Disord

Specialty Neurology

Date 2020 Jul 23

PMID 32698095

Citations 92

Authors

M Palao

E Fernandez-Diaz

J Gracia-Gil

C M Romero-Sanchez

I Diaz-Maroto

T Segura

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.

Citing Articles

NETosis: A key player in autoimmunity, COVID-19, and long COVID.

Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.

PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.

The impact of social and environmental factors on triggering multiple sclerosis onset, before and during the COVID-19 pandemic: a retrospective study from Iran.

Kasbi N, Ghadiri F, Naser Moghadasi A, Khodaie F, Kohandel K, Rezaeimanesh N BMC Neurol. 2024; 24(1):453.

PMID: 39563293 PMC: 11575067. DOI: 10.1186/s12883-024-03956-x.

Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.

Guo M, Shang S, Li M, Cai G, Li P, Chen X Med Rev (2021). 2024; 4(5):367-383.

PMID: 39444797 PMC: 11495526. DOI: 10.1515/mr-2024-0013.

Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies.

Hollist M, Hollist A, Au K, Betts C, Kirmani M, Kirmani M Neurosci Insights. 2024; 19:26331055241265668.

PMID: 39347459 PMC: 11437550. DOI: 10.1177/26331055241265668.

Ocular Implications of COVID-19 Infection and Vaccine-Related Adverse Events.

Parmar U, Surico P, Singh R, Musa M, Scarabosio A, Surico G J Pers Med. 2024; 14(8).

PMID: 39201972 PMC: 11355216. DOI: 10.3390/jpm14080780.

References

Shindler K, Kenyon L, Dutt M, Hingley S, Das Sarma J . Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus. J Virol. 2008; 82(17):8882-6. PMC: 2519666. DOI: 10.1128/JVI.00920-08. View

McKay K, Jahanfar S, Duggan T, Tkachuk S, Tremlett H . Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology. 2016; 61:189-212. DOI: 10.1016/j.neuro.2016.03.020. View

Houtman J, Fleming J . Pathogenesis of mouse hepatitis virus-induced demyelination. J Neurovirol. 1996; 2(6):361-76. DOI: 10.3109/13550289609146902. View

Marrodan M, Alessandro L, Farez M, Correale J . The role of infections in multiple sclerosis. Mult Scler. 2019; 25(7):891-901. DOI: 10.1177/1352458518823940. View

Desforges M, Le Coupanec A, Stodola J, Meessen-Pinard M, Talbot P . Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014; 194:145-58. PMC: 7114389. DOI: 10.1016/j.virusres.2014.09.011. View

Savarin C, Bergmann C . Viral-induced suppression of self-reactive T cells: Lessons from neurotropic coronavirus-induced demyelination. J Neuroimmunol. 2017; 308:12-16. PMC: 5474352. DOI: 10.1016/j.jneuroim.2017.01.003. View

MURRAY R, Brown B, Brian D, Cabirac G . Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol. 1992; 31(5):525-33. PMC: 7159714. DOI: 10.1002/ana.410310511. View

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti M, Santoro P . Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2020; 7(4). PMC: 7217652. DOI: 10.1212/NXI.0000000000000741. View

Romero-Sanchez C, Diaz-Maroto I, Fernandez-Diaz E, Sanchez-Larsen A, Layos-Romero A, Garcia-Garcia J . Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8):e1060-e1070. PMC: 7668545. DOI: 10.1212/WNL.0000000000009937. View

10.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J . A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020; 94:55-58. PMC: 7195378. DOI: 10.1016/j.ijid.2020.03.062. View

11.

Zanin L, Saraceno G, Panciani P, Renisi G, Signorini L, Migliorati K . SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020; 162(7):1491-1494. PMC: 7197630. DOI: 10.1007/s00701-020-04374-x. View

12.

Matias-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu J . Should we expect neurological symptoms in the SARS-CoV-2 epidemic?. Neurologia (Engl Ed). 2020; 35(3):170-175. PMC: 7136883. DOI: 10.1016/j.nrl.2020.03.001. View

13.

Zhao H, Shen D, Zhou H, Liu J, Chen S . Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol. 2020; 19(5):383-384. PMC: 7176927. DOI: 10.1016/S1474-4422(20)30109-5. View

14.

Andersen O, Lygner P, Bergstrom T, Andersson M, Vahlne A . Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol. 1993; 240(7):417-22. DOI: 10.1007/BF00867354. View

15.

Donati D . Viral infections and multiple sclerosis. Drug Discov Today Dis Models. 2020; 32:27-33. PMC: 7102669. DOI: 10.1016/j.ddmod.2020.02.003. View